<DOC>
	<DOCNO>NCT00287729</DOCNO>
	<brief_summary>The purpose study assess efficacy treatment pirfenidone 2403 milligram per day compare placebo patient idiopathic pulmonary fibrosis ( IPF ) ass safety treatment pirfenidone 2403 milligram per day compare placebo patient idiopathic pulmonary fibrosis .</brief_summary>
	<brief_title>Safety Efficacy Pirfenidone Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , safety efficacy study pirfenidone patient idiopathic pulmonary fibrosis ( IPF ) . Approximately 320 patient approximately 50 center randomly assign ( 1:1 ) receive pirfenidone 2403 milligram placebo equivalent administer divided dos three time per day ( TID ) food . The primary outcome variable absolute change percent predict Forced Vital Capacity Baseline Week 72 . Patients randomize geographic region . Patients receive blind study treatment time randomization last patient randomize treated 72 week . A Data Monitoring Committee ( DMC ) periodically review safety efficacy data ensure patient safety . After week 72 , patient meet Progression Disease ( POD ) definition , ≥ 10 % absolute decrease percent predict Forced Vital Capacity ≥ 15 % absolute decrease percent predict carbon monoxide diffuse capacity ( DLco ) , eligible receive permit idiopathic pulmonary fibrosis therapy addition blind study drug . Permitted idiopathic pulmonary therapy include corticosteroid , azathioprine , cyclophosphamide N-acetyl-cysteine ( restriction ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Primary Inclusion criterion : diagnosis idiopathic pulmonary fibrosis 40 80 year age Forced Vital Capacity ≥ 50 % predict value carbon monoxide diffuse capacity ( DLco ) ≥ 35 % predict value either Forced Vital Capacity carbon monoxide diffuse capacity ( DLco ) ≤ 90 % predict value improvement past year able walk 150 meter 6 minute maintain saturation ≥ 83 % 6 liter per minute supplemental oxygen Primary Exclusion criterion : unable undergo pulmonary function test evidence significant obstructive lung disease airway hyperresponsiveness clinical opinion investigator , patient expect need eligible lung transplant within 72 week randomization active infection liver disease cancer medical condition likely result death within 2 year diabetes pregnancy lactation substance abuse personal family history long QT syndrome IPF treatment unable take study medication withdrawal IPF trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Lung</keyword>
	<keyword>Pirfenidone</keyword>
	<keyword>InterMune</keyword>
</DOC>